Novogen (NASDAQ:KZIA) Stock Rating Upgraded by Wall Street Zen

Novogen (NASDAQ:KZIA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently commented on KZIA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research note on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Novogen in a report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Novogen presently has an average rating of “Hold” and an average price target of $19.00.

Novogen Price Performance

NASDAQ:KZIA opened at $8.45 on Friday. The business’s 50-day simple moving average is $6.63 and its two-hundred day simple moving average is $7.72. Novogen has a 52 week low of $2.86 and a 52 week high of $17.40.

Novogen (NASDAQ:KZIA) last issued its earnings results on Friday, November 7th. The company reported ($6.14) earnings per share (EPS) for the quarter. The company had revenue of $0.59 million during the quarter.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.